Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-α and Chemokine Production by Human Lung Parenchyma

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Buenestado, Amparo ^a   Chaumais, Marie Camille ^a   Grassin Delyle, Stanislas ^a   Risse, Paul André ^a   Naline, Emmanuel ^a   Longchampt, Elisabeth ^b   Tenor, Hermann ^c   Devillier, Philippe ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b FOCH HOSPITAL   (France)

^c Nycomed: A Takeda Company   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL9 CHEMOKINE; CYCLIC AMP; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FORMOTEROL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDOMETACIN; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PROSTAGLANDIN E2; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL TRANSPORT; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXPLANT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IN VITRO STUDY; INHIBITION KINETICS; LIMIT OF DETECTION; LUNG HOMOGENATE; LUNG PARENCHYMA; LUNG RESECTION; MALE; MONOCYTE; NEUTROPHIL; SUPERNATANT; T LYMPHOCYTE;

AMINOPYRIDINES; BENZAMIDES; CHEMOKINES; CYCLOPROPANES; HUMANS; LIPOPOLYSACCHARIDES; LUNG; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884171273     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074640     Document Type: Article

References (59)

1. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, et al. (2010) The preclinical pharmacology of roflumilast- a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23: 235-256. doi:10.1016/j.pupt.2010.03.011. PubMed: 20381629.
2. Giembycz MA, Field SK, (2010) Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 4: 147-158. PubMed: 20689641.
3. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, et al. (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363: 1128-1138. doi:10.1056/NEJMoa0909883. PubMed: 20843247.
4. Tashkin DP, (2010) Frequent exacerbations of chronic obstructive pulmonary disease--a distinct phenotype? N Engl J Med 363: 1183-1184. doi:10.1056/NEJMe1008184. PubMed: 20843256.
5. Hatzelmann A, Schudt C, (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297: 267-279. PubMed: 11259554.
6. Lahu G, Hünnemeyer A, Diletti E, Elmlinger M, Ruth P, et al. (2010) Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet 49: 589-606. doi:10.2165/11536600-000000000-00000. PubMed: 20690782.
7. Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, et al. (2007) Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 47: 26-36. doi:10.1177/0091270006294529. PubMed: 17192499.
8. Buenestado A, Grassin-Delyle S, Guitard F, Naline E, Faisy C, et al. (2012) Roflumilast inhibits the release of chemokines and TNF-alpha from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol 165: 1877-1890. doi:10.1111/j.1476-5381.2011.01667.x. PubMed: 21913898.
9. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, et al. (2002) Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57: 759-764. doi:10.1136/thorax.57.9.759. PubMed: 12200518.
10. Parameswaran GI, Sethi S, Murphy TF, (2011) Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD. Chest 140: 611-617. doi:10.1378/chest.10-2760. PubMed: 21349930.
11. Kharitonov SA, Sjöbring U, (2007) Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib Microbiol 14: 83-100. PubMed: 17684334.
12. Zhang H, Kim YK, Govindarajan A, Baba A, Binnie M, et al. (1999) Effect of adrenoreceptors on endotoxin-induced cytokines and lipid peroxidation in lung explants. Am J Respir Crit Care Med 160: 1703-1710. doi:10.1164/ajrccm.160.5.9903068. PubMed: 10556144.
13. Hackett TL, Holloway R, Holgate ST, Warner JA, (2008) Dynamics of pro-inflammatory and anti-inflammatory cytokine release during acute inflammation in chronic obstructive pulmonary disease: an ex vivo study. Respir Res 9: 47. doi:10.1186/1465-9921-9-47. PubMed: 18510721.
14. Mitsuta K, Shimoda T, Fukushima C, Obase Y, Ayabe H, et al. (2001) Preoperative steroid therapy inhibits cytokine production in the lung parenchyma in asthmatic patients. Chest 120: 1175-1183. doi:10.1378/chest.120.4.1175. PubMed: 11591557.
15. Keatings VM, Collins PD, Scott DM, Barnes PJ, (1996) Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153: 530-534. doi:10.1164/ajrccm.153.2.8564092. PubMed: 8564092.
16. Capelli A, Di Stefano A, Gnemmi I, Balbo P, Cerutti CG, et al. (1999) Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J 14: 160-165. doi:10.1034/j.1399-3003.1999.14a27.x. PubMed: 10489845.
17. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE, (2002) Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 57: 590-595. doi:10.1136/thorax.57.7.590. PubMed: 12096201.
18. Costa C, Rufino R, Traves SL, Lapa E Silva JR, Barnes PJ, et al. (2008) CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 133: 26-33. doi:10.1378/chest.07-0393. PubMed: 17925429.
19. Barnes PJ, (2009) The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 41: 631-638. doi:10.1165/rcmb.2009-0220TR. PubMed: 19717810.
20. Chung KF, Caramori G, Adcock IM, (2009) Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 65: 853-871. doi:10.1007/s00228-009-0682-z. PubMed: 19557399.
21. Alifano M, Cuvelier A, Delage A, Roche N, Lamia B, et al. (2010) Treatment of COPD: from pharmacological to instrumental therapies. Eur Respir Rev 19: 7-23. doi:10.1183/09059180.00008009. PubMed: 20956161.
22. Rodrigo GJ, Castro-Rodriguez JA, Plaza V, (2009) Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 136: 1029-1038. doi:10.1378/chest.09-0821. PubMed: 19633090.
23. Keravis T, Thaseldar-Roumié R, Lugnier C, (2005) Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol Biol 307: 63-74. PubMed: 15988055.
24. Tenor H, Hedbom E, Häuselmann HJ, Schudt C, Hatzelmann A, (2002) Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4. Br J Pharmacol 135: 609-618. doi:10.1038/sj.bjp.0704480. PubMed: 11834608.
25. Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF, (2002) Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax 57: 237-241. doi:10.1136/thorax.57.3.237. PubMed: 11867828.
26. Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, et al. (2010) Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 334: 53-62. doi:10.1124/jpet.110.167007. PubMed: 20371707.
27. Flanagan PG, Jackson SK, Findlay G, (2001) Diagnosis of gram negative, ventilator associated pneumonia by assaying endotoxin in bronchial lavage fluid. J Clin Pathol 54: 107-110. doi:10.1136/jcp.54.2.107. PubMed: 11215277.
28. Nys M, Deby-Dupont G, Habraken Y, Legrand-Poels S, Kohnen S, et al. (2003) Bronchoalveolar lavage fluids of ventilated patients with acute lung injury activate NF-kappaB in alveolar epithelial cell line: role of reactive oxygen/nitrogen species and cytokines. Nitric Oxide 9: 33-43. doi:10.1016/j.niox.2003.07.001. PubMed: 14559430.
29. Martin TR, Rubenfeld GD, Ruzinski JT, Goodman RB, Steinberg KP, et al. (1997) Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 155: 937-944. doi:10.1164/ajrccm.155.3.9117029. PubMed: 9117029.
30. Miller EJ, Cohen AB, Nagao S, Griffith D, Maunder RJ, et al. (1992) Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis 146: 427-432. doi:10.1164/ajrccm/146.2.427. PubMed: 1489135.
31. Spina D, (2008) PDE4 inhibitors: current status. Br J Pharmacol 155: 308-315. PubMed: 18660825.
32. Yougbare I, Morin C, Senouvo FY, Sirois C, Albadine R, et al. (2011) NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues. Am J Physiol Lung Cell Mol Physiol 301: L441-L450. doi:10.1152/ajplung.00407.2010. PubMed: 21784969.
33. Fotheringham JA, Mayne MB, Grant JA, Geiger JD, (2004) Activation of adenosine receptors inhibits tumor necrosis factor-alpha release by decreasing TNF-alpha mRNA stability and p38 activity. Eur J Pharmacol 497: 87-95. doi:10.1016/j.ejphar.2004.06.029. PubMed: 15321739.
34. Kreckler LM, Gizewski E, Wan TC, Auchampach JA, (2009) Adenosine suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production by murine macrophages through a protein kinase A- and exchange protein activated by cAMP-independent signaling pathway. J Pharmacol Exp Ther 331: 1051-1061. doi:10.1124/jpet.109.157651. PubMed: 19749080.
35. Bryn T, Mahic M, Enserink JM, Schwede F, Aandahl EM, et al. (2006) The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J Immunol 176: 7361-7370. PubMed: 16751380.
36. Hallsworth MP, Twort CH, Lee TH, Hirst SJ, (2001) beta(2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br J Pharmacol 132: 729-741. doi:10.1038/sj.bjp.0703866. PubMed: 11159726.
37. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr, et al. (2002) Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277: 44147-44154.
38. Delgado M, Ganea D, (2001) Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 167: 966-975. PubMed: 11441105.
39. Hogg JC, Timens W, (2009) The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4: 435-459. doi:10.1146/annurev.pathol.4.110807.092145. PubMed: 18954287.
40. Martorana PA, Lunghi B, Lucattelli M, De Cunto G, Beume R, et al. (2008) Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice. BMC Pulm Med 8: 17. doi:10.1186/1471-2466-8-17. PubMed: 18755021.
41. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, et al. (2003) Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168: 976-982. doi:10.1164/rccm.200212-1490OC. PubMed: 12816740.
42. Donnelly LE, Tudhope SJ, Fenwick PS, Barnes PJ, (2010) Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages. Eur Respir J 36: 178-186. doi:10.1183/09031936.00158008. PubMed: 19926732.
43. Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, et al. (1997) Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Gen Pharmacol 29: 633-638. doi:10.1016/S0306-3623(96)00580-0. PubMed: 9352314.
44. Kaur M, Holden NS, Wilson SM, Sukkar MB, Chung KF, et al. (2008) Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. Am J Physiol Lung Cell Mol Physiol 295: L505-L514. doi:10.1152/ajplung.00046.2008. PubMed: 18586957.
45. Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, et al. (2010) The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol 159: 1304-1311. doi:10.1111/j.1476-5381.2009.00614.x. PubMed: 20136829.
46. Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, Schaumann F, Mueller M, et al. (2008) Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther 21: 616-623. doi:10.1016/j.pupt.2008.02.002. PubMed: 18374614.
47. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, et al. (2007) Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62: 1081-1087. doi:10.1136/thx.2006.075937. PubMed: 17573446.
48. Sanz MJ, Cortijo J, Taha MA, Cerdá-Nicolás M, Schatton E, et al. (2007) Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol 152: 481-492. doi:10.1038/sj.bjp.0707428. PubMed: 17704822.
49. Holden NS, Rider CF, Bell MJ, Velayudhan J, King EM, et al. (2010) Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action. Br J Pharmacol 160: 410-420. doi:10.1111/j.1476-5381.2010.00708.x. PubMed: 20423350.
50. Hung CH, Chu YT, Hua YM, Hsu SH, Lin CS, et al. (2008) Effects of formoterol and salmeterol on the production of Th1- and Th2-related chemokines by monocytes and bronchial epithelial cells. Eur Respir J 31: 1313-1321. doi:10.1183/09031936.00121406. PubMed: 18256057.
51. Hatzelmann A, Tenor H, Schudt C, (1995) Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol 114: 821-831. doi:10.1111/j.1476-5381.1995.tb13278.x. PubMed: 7539697.
52. Au BT, Teixeira MM, Collins PD, Williams TJ, (1998) Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br J Pharmacol 123: 1260-1266. doi:10.1038/sj.bjp.0701723. PubMed: 9559913.
53. Seldon PM, Barnes PJ, Meja K, Giembycz MA, (1995) Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 48: 747-757. PubMed: 7476903.
54. Tannheimer SL, Sorensen EA, Haran AC, Mansfield CN, Wright CD, et al. (2012) Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells. Pulm Pharmacol Ther 25: 178-184. doi:10.1016/j.pupt.2012.01.003. PubMed: 22306235.
55. Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H, et al. (2002) PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 26: 694-701. doi:10.1165/ajrcmb.26.6.4743. PubMed: 12034568.
56. Fann YD, Rothberg KG, Tremml PG, Douglas JS, DuBois AB, (1986) Ascorbic acid promotes prostanoid release in human lung parenchyma. Prostaglandins 31: 361-368. PubMed: 3515431.
57. Bateman ED, Rabe KF, Calverley PM, Goehring UM, Brose M, et al. (2011) Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur Respir J 38: 553-560. doi:10.1183/09031936.00178710. PubMed: 21737553.
58. Kochetkova M, Burns FM, Souness JE, (1995) Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram. Biochem Pharmacol 50: 2033-2038. doi:10.1016/0006-2952(95)02104-3. PubMed: 8849330.
59. Torphy TJ, Zhou HL, Cieslinski LB, (1992) Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J Pharmacol Exp Ther 263: 1195-1205. PubMed: 1335058.